These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3117833)

  • 21. Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type 1 diabetes.
    Paolisso G; Sgambato S; Torella R; Varricchio M; Scheen A; D'Onofrio F; Lefèbvre PJ
    J Clin Endocrinol Metab; 1988 Jun; 66(6):1220-6. PubMed ID: 3286673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
    Landstedt-Hallin L; Adamson U; Lins PE
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3140-5. PubMed ID: 10487677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.
    Tuttle KR; Bruton JL; Perusek MC; Lancaster JL; Kopp DT; DeFronzo RA
    N Engl J Med; 1991 Jun; 324(23):1626-32. PubMed ID: 2030719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiological insulin replacement in type 1 diabetes mellitus.
    Bolli GB
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S317-32. PubMed ID: 11460580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Undiagnosed asymptomatic hypoglycemia: diet, insulin, and glyburide for gestational diabetic pregnancy.
    Yogev Y; Ben-Haroush A; Chen R; Rosenn B; Hod M; Langer O
    Obstet Gynecol; 2004 Jul; 104(1):88-93. PubMed ID: 15229005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
    Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O
    J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-mediated glucose disposal in type 1 (insulin-dependent) diabetic subjects treated by continuous subcutaneous or intraperitoneal insulin fusion.
    Beylot M; Khalfallah Y; Laville M; Sautot G; Dechaud H; Serusclat P; Berthezene F; Riou JP; Mornex R
    Diabete Metab; 1987; 13(4):450-6. PubMed ID: 3315766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advantageous metabolic effects of pulsatile insulin delivery in noninsulin-dependent diabetic patients.
    Paolisso G; Sgambato S; Gentile S; Memoli P; Giugliano D; Varricchio M; D'Onofrio F
    J Clin Endocrinol Metab; 1988 Nov; 67(5):1005-10. PubMed ID: 3053747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
    Hother-Nielsen O; Schmitz O; Andersen PH; Pedersen O; Beck-Nielsen H
    Diabetes Res; 1988 Jun; 8(2):63-70. PubMed ID: 3147830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenous insulin delivery in humans with type 1 diabetes.
    Hipszer B; Joseph J; Kam M
    Diabetes Technol Ther; 2005 Feb; 7(1):83-93. PubMed ID: 15738706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin action in insulin-dependent diabetics after short-term thiazide therapy.
    Schmitz O; Hermansen K; Nielsen OH; Christensen CK; Arnfred J; Hansen HE; Mogensen CE; Orskov H; Beck-Nielsen H
    Diabetes Care; 1986; 9(6):631-6. PubMed ID: 3542455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative roles of insulin clearance and insulin sensitivity in the prebreakfast increase in insulin requirements in insulin-dependent diabetic patients.
    Skor DA; White NH; Thomas L; Santiago JV
    Diabetes; 1984 Jan; 33(1):60-3. PubMed ID: 6360768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide.
    Burke BJ; Hartog M; Waterfield MR
    Acta Endocrinol (Copenh); 1984 Sep; 107(1):70-7. PubMed ID: 6435371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occurrence of dawn phenomenon without change in insulin clearance in patients with insulin-dependent diabetes mellitus.
    Campbell PJ; Gerich JE
    Diabetes; 1986 Jul; 35(7):749-52. PubMed ID: 3522315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind study of the efficacy of neutral human and porcine insulin in type I diabetes using a glucose-controlled insulin infusion system.
    Christensen SE; Schmitz O; Hansen AP; Jensen I; Heding L
    Metabolism; 1984 Sep; 33(9):864-8. PubMed ID: 6381963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of porcine and semisynthetic human insulins using euglycemic clamp-derived glucose-insulin dose-response curves in insulin-dependent diabetes.
    Staten M; Worcester B; Szekeres A; Waldeck N; Ascher M; Walsh KM; Rizza R; Gerich J; Charles MA
    Metabolism; 1984 Feb; 33(2):132-5. PubMed ID: 6363874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for the programming of an open-loop insulin infusion device from the biostator glucose controller.
    Service FJ; Rizza RA; Westland RE; Hall LD; Nelson RL; Haymond MW; Clemens AH; Gerich JE
    Diabetes Care; 1980; 3(2):278-84. PubMed ID: 6993141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulphonylurea and insulin: combined treatment in type 1 (insulin-dependent) diabetes.
    Burke BJ
    Diabetologia; 1985 Mar; 28(3):182. PubMed ID: 3922830
    [No Abstract]   [Full Text] [Related]  

  • 40. A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.
    Gillespie WR; Veng-Pedersen P; Antal EJ; Phillips JP
    J Pharm Sci; 1988 Jan; 77(1):48-55. PubMed ID: 3126291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.